Navigation Links
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Date:10/12/2009

NEW HAVEN, Conn., Oct. 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options.

As previously reported, the Oncologic Drugs Advisory Committee (ODAC), which is the cancer drug advisory panel of the U.S. Food and Drug Administration (FDA), voted in favor of Vion completing a randomized study defining the efficacy and safety of the Company's lead oncology therapeutic Onrigin(TM) (laromustine) Injection prior to receiving regulatory approval from the FDA. Vion had presented data for Onrigin(TM) for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). As Vion would need to raise additional capital to finance a new randomized trial, the Company is evaluating its strategic alternatives. If Vion is unsuccessful in achieving a restructuring, sale, financing or any other strategic transaction or combination thereof, it may have to consider curtailing or ceasing operations or liquidating its assets.

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM) (laromustine) Injection and Triapine®. The Company has submitted a New Drug Application to the FDA for Onrigin(TM) for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrig
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Biopsy Devices ... GlobalData,s new report, "BRIC Biopsy Devices Market Outlook ... Biopsy Devices market. The report provides value, in millions ... (in US dollars) within market segments - Biopsy Guns ... Fine Aspiration Needles (Disposable and Reusable Fine Aspiration Needles) ...
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... 2014 /PRNewswire-iReach/ -- ChemImage announced today the ... in the development of imaging technology used ... and diseased tissue that minimizes the learning ... lowers surgical costs and potentially enhances patient ... The clinical and scientific teams at ...
Breaking Medicine Technology:BRIC Biopsy Devices Market Outlook to 2020 2BRIC Biopsy Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... , , DURHAM, N.C., Jan. 8 Oxygen ... common stock has been approved for listing on the NASDAQ ... to the NASDAQ is a very important milestone for our ... listed on the NASDAQ provides us with greater visibility for ...
... , , , FARMINGDALE, N.Y., Jan. ... of minimally invasive ultrasonic medical device technology, which in Europe ... other acute health conditions, has entered into a new, three ... in Riyadh, Kingdom of Saudi Arabia, for the distribution of ...
Cached Medicine Technology:Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing 2Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia 2Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia 3
(Date:9/17/2014)... Present-day Europeans are the descendants of at least ... new study. Previous research suggested that ... farmers. But, a new genetic analysis involving ancient ... of Ancient North Eurasians. Nearly all present-day Europeans ... researchers from Harvard Medical School said. , , ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 (HealthDay ... why antibiotic-resistant bacteria can thrive in a hospital setting. ... the culprit. They can easily enter bacteria and move from ... makes bacteria drug-resistant, a new study finds. "The plasmids ... class of antibiotic called carbapenems," said the study,s co-author, Dr. ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
(Date:9/17/2014)... 17, 2014 Today, Blue Shield ... in third-quarter grantmaking. This body of grants aims to ... innovations in care delivery, as well as to develop ... Grants will also strengthen the capacity of both domestic ... and create new entry points for domestic violence screening ...
(Date:9/17/2014)... 17, 2014 In a country where ... on a regular basis, how can Americans find healthy ... Hyland’s Stress Challenge , a 5-day interactive journey ... stress-free life. From September 29th – October 3rd, ... content relating to specific topics that promote natural solutions ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Blue Shield of California Foundation Awards $5 Million in Third-Quarter Grants 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2
... to this new research on mountain biking it is observed ... from University Hospital in Innsbruck, Austria,// presented his findings of ... extreme mountain bikers and 30 non-bikers took part in the ... more than two hours a day, six days a week, ...
... effective utility tool to the field of medicine. An ... about their treatment. The days when doctors told you ... expect to participate in the decision-making process. But sometimes ... messages and new research comes up all the time. ...
... are more likely to suffer from behavioural problems, a ... growth hormone not only boosted growth in children,// but ... ,Lead researcher Dr Derick Beens, professor of ... said: "We believe this work demonstrates that all very ...
... has always been an ongoing argument regarding the do's and ... suggest a new and better way through the dieting controversy.// ... fashion being the 'low carb' approach - for many decades ... at the 'no diet' women's retreat Green Mountain in the ...
... events in detail, older people recall more about thoughts, ... age - some researchers believe that it deteriorates,// others ... Psychologists in Toronto have been comparing how people of ... ,They studied a group of 15 younger ...
... is better than conventional treatment for managing asthma ... of immune cells known eosinophils increase// in the ... at how targeting this build up of eosinophils ... an asthma attack. ,The conventional treatment ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: